PEDIATRICS Vol. 89 No. 4 April 1992, pp. 805-806
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WHITMAN, B. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WHITMAN, B. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Dosage of Carbamazepine (Tegretol) Suspension

BRADLEY W. WHITMAN MD1

1 Department of Neurology, Children's National Medical Center, Washington, DC

To the Editor.—

The current edition (12th) of The Harriet Lane Handbook contains an error which should be brought to the attention of readers and clinicians referring to this publication.

In the medication dosage section of the Handbook, Tegretol is listed, incorrectly, as being available in a suspension of 100 mg/mL, while the only suspension form of this product which is commercially available is the 100 mg/5 mL form.1,2 This has been confirmed with the Ciba-Geigy Company which manufacturers Tegretol (Ciba-Geigy, personal communication, November 1991).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?